Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pixantrone - Servier

Drug Profile

Pixantrone - Servier

Alternative Names: BBR-2278; BBR-2778; Pixantrone dimaleate; Pixuvri

Latest Information Update: 10 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Vermont
  • Developer Cell Therapeutics; Neopharm Ltd; Servier
  • Class Anthracyclines; Anthraquinones; Antineoplastics; Isoquinolines; Small molecules
  • Mechanism of Action Alkylating agents; Immunosuppressants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-Hodgkin's lymphoma
  • Phase III Diffuse large B cell lymphoma; Follicular lymphoma
  • No development reported Cancer
  • Discontinued Breast cancer; Myasthenia gravis

Most Recent Events

  • 02 Oct 2023 CTI Biopharma withdraws a phase I trial in Cancer (Metastatic disease, Second-line therapy) in USA, prior to enrolment (NCT01632436)
  • 05 Oct 2020 CTI BioPharma withdraws a phase III trial prior to enrollment for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT00577161) (NCT00551239)
  • 28 Nov 2019 No recent reports of development identified for phase-I development in Cancer(In adolescents, In children, In infants, Monotherapy, Second-line therapy or greater, In adults) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top